Ambry Genetics Agrees to Pay Roche Royalties Due for Licensing of PCR Technology.

Roche, Ambry Settle Royalties Dispute

PLEASANTON, Calif. -- Roche Diagnostics today announced that its royalty dispute with Ambry Genetics has been settled. The dispute involved Roche's Patent Portfolio for Polymerase Chain Reaction (PCR) and related technology.

Under the terms of the settlement, Ambry will pay Roche Diagnostics past royalties due in the field of Human In Vitro Diagnostics, and Roche Diagnostics has agreed to dismiss the arbitration proceedings it had initiated.

"Ambry acted in a completely responsible way after being advised of its obligations under our license agreement," said Melinda Griffith, Senior Vice President and General Counsel at Roche Molecular Diagnostics, a business area of Roche Diagnostics. "Roche Diagnostics will continue to take all necessary action to safeguard our intellectual property."

Roche Diagnostics has an active patent licensing program in which it makes available technology improvement patents for the company's Nobel-prize winning PCR technology. These patents involve the use of PCR in such areas as real time nucleic acid quantitation, reverse transcription, and many advanced polymerase enzymes.

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2005 sales by the Pharmaceuticals Division totaled 27.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our websites www.roche.com and www.roche-diagnostics.com

About Ambry Genetics

A worldwide leader in specialized genetic testing, California based Ambry Genetics Corporation provides health providers precise, cost-effective methods of molecular biology laboratory testing of specific genes to aid in early, more accurate diagnosis and disease definition to broaden the approaches to inherited disease management and provide the basis for more effective treatments and targeted prevention.

All trademarks used or mentioned in this release are legally protected by law.